URAC Rare Disease Pharmacy Certification vs. Specialty Pharmacy Accreditation — Which Credential Does Your Pharmacy Need?

Last updated: November 2026

Specialty pharmacies serving rare and orphan disease patient populations have more than one quality credential available — and the choice between them is consequential. URAC Rare Disease Pharmacy Center of Excellence Certification, URAC Specialty Pharmacy Accreditation, and ACHC specialty pharmacy programs each address different market requirements and serve different strategic purposes. This comparison explains what each credential is, how they relate to each other, and how to determine which path your pharmacy needs.

The Specialty Pharmacy Accreditation Landscape

URAC and ACHC (Accreditation Commission for Health Care) both accredit specialty pharmacies, as do NABP and The Joint Commission. URAC and ACHC each offer a rare disease credential that builds on that accreditor's pharmacy accreditation: URAC's Rare Disease Pharmacy Center of Excellence Certification and ACHC's distinction in Rare Diseases and Orphan Drugs. The choice between them turns on which accreditor the manufacturers and payers you work with ask for.

Understanding how these programs relate to each other is the starting point for any accreditation strategy conversation.

The URAC Specialty Pharmacy Program Structure

URAC offers two pharmacy quality programs relevant to rare disease:

  • URAC Specialty Pharmacy Accreditation — a standalone three-year credential covering nine operational modules. This is the foundational credential Rare Disease Certification builds on.
  • URAC Rare Disease Pharmacy Center of Excellence Certification — a specialized certification layered on top of Specialty Pharmacy Accreditation, adding five standards specific to rare and orphan disease patient management.

These are not alternative paths. Rare Disease Certification builds on Specialty Pharmacy Accreditation. The question is not which one to pursue — it is whether to pursue Specialty Pharmacy Accreditation alone or Specialty Pharmacy Accreditation plus Rare Disease Certification.

URAC Rare Disease Certification vs. URAC Specialty Pharmacy Accreditation

Dimension URAC Specialty Pharmacy Accreditation URAC Rare Disease Pharmacy Center of Excellence Certification
Program type Standalone accreditation Certification overlay (builds on Specialty Pharmacy Accreditation)
Standards covered 9 modules: Risk Management, Operations and Infrastructure, Performance Monitoring and Improvement, Consumer Protection and Empowerment, Pharmacy Operations, Medication Distribution, Patient Service and Communication, Patient Management, Reporting Performance Measures All 9 Specialty Pharmacy modules PLUS 5 additional rare disease standards: rare disease-specific assessment, disease-specific education, multidisciplinary collaboration, rare disease analytics, rare disease CQI
Eligibility requirement Dispenses specialty medications and provides patient management services Holds or is actively seeking URAC Specialty Pharmacy Accreditation AND actively dispenses at least one rare or orphan medication
Drug focus All specialty medications Rare and orphan disease medications (Orphan Drug Act designees)
Primary market signal Baseline specialty pharmacy credential; recognition varies by payer, health plan and health system Rare disease-specific credential; recognition varies by manufacturer and payer
Manufacturer network access Criteria vary; confirm what each manufacturer asks for Criteria vary; confirm what each manufacturer asks for
Patient management standard Specialty patient management across the full specialty drug portfolio Disease-specific patient assessment tailored to each rare condition dispensed
Education requirements Patient service and communication standards applicable to all specialty conditions Disease-specific education programs for patients, caregivers, providers, and payers — one program per rare disease, not a general program
Care team requirements Qualified pharmacy staff providing patient management services Documented multidisciplinary team collaboration with evidence of actual cross-discipline interaction events
Analytics requirements Performance measure reporting across required specialty pharmacy metrics Population-level data collection and analytics tracking rare disease patient outcomes specifically
CQI requirements Performance monitoring and improvement program across general specialty pharmacy operations CQI program evaluated specifically against rare disease performance measures with documented improvement activity
Developed with Pharmacy industry stakeholders Pharmacy industry stakeholders plus NORD — National Organization for Rare Disorders
Survey method Document review, policy review, patient file audit across 9 modules Same as Specialty Pharmacy Accreditation plus additional review of the 5 rare disease standards

URAC vs. ACHC for Rare Disease Pharmacy

ACHC (Accreditation Commission for Health Care) also accredits specialty pharmacies. The comparison matters when a pharmacy is choosing its foundational specialty pharmacy credential, because each accreditor's rare disease credential sits on that accreditor's own base accreditation.

Dimension URAC Specialty Pharmacy + Rare Disease Certification ACHC Specialty Pharmacy + Rare Diseases and Orphan Drugs Distinction
Rare disease-specific designation Yes — Rare Disease Pharmacy Center of Excellence Certification available as overlay Yes: distinction in Rare Diseases and Orphan Drugs, earned with or after ACHC Pharmacy Accreditation
Limited-distribution drug positioning Rare disease-specific certification; confirm what each manufacturer asks for Rare disease-specific distinction; ACHC requires an agreed collaboration between the pharmacy and the manufacturer and the ability to act on treatment journey data; confirm what each manufacturer asks for
Standards structure 9 modules at accreditation level, plus 5 rare disease-specific standards at certification level ACHC pharmacy standards, plus the distinction, which ACHC says covers patient management, employee education, and medication handling and dispensing
NORD collaboration Rare Disease standards developed with NORD input None named on ACHC's pharmacy page
Payer and health plan recognition Recognition varies by health plan and payer; confirm what each contract requires Recognition varies by health plan and payer; confirm what each contract requires
Best for Pharmacies whose payer, health system or manufacturer relationships call for URAC recognition, including URAC's rare disease certification Pharmacies whose payer, health system or manufacturer relationships call for ACHC recognition, including ACHC's rare disease distinction

The Decision Rule

If your pharmacy's strategic objective includes rare disease drug access and manufacturer limited-distribution network positioning, start from the accreditor your manufacturer partners ask for. URAC and ACHC each offer a rare disease credential, and each sits on that accreditor's own base accreditation. A pharmacy accredited by ACHC can pursue ACHC's distinction, or add URAC Specialty Pharmacy Accreditation to reach URAC's certification, so starting with ACHC does not close off the URAC path.

If your existing health plan and payer contracts require ACHC specifically, ACHC may be the necessary baseline. Some pharmacies hold both URAC and ACHC accreditation to satisfy different contract populations. IHS evaluates your specific contracting relationships in the discovery session and recommends the appropriate path.

Which Path Is Right for Your Pharmacy?

Pursue URAC Specialty Pharmacy Accreditation Only If:

  • Your pharmacy dispenses specialty medications but has limited rare disease drug portfolio exposure
  • Your primary market positioning goal is payer and health plan network access, not rare disease manufacturer partnerships
  • You are building toward Rare Disease Certification but are not yet actively dispensing orphan medications
  • Your organization is establishing foundational quality credentials before pursuing advanced designation

Pursue URAC Rare Disease Pharmacy Center of Excellence Certification If:

  • Your pharmacy actively dispenses one or more rare or orphan medications — you meet the drug-dispensing eligibility criterion
  • You are pursuing or planning to pursue limited-distribution drug contracts with rare disease manufacturers
  • Your pharmacy is competing for rare disease patient volumes against large national specialty pharmacy operators
  • You hold URAC Specialty Pharmacy Accreditation and want to differentiate on quality in the rare disease market
  • Your clinical team already operates with multidisciplinary care coordination for rare disease patients — the certification documents what you are already doing

Pursue ACHC Pharmacy Accreditation with the Rare Diseases and Orphan Drugs Distinction If:

  • Your manufacturer partners and payers ask for ACHC
  • Your pharmacy already holds, or is pursuing, ACHC Pharmacy Accreditation
  • You have a clear, agreed collaboration with the manufacturer and can collect, analyze, report on and act on treatment journey data

Pursue Both URAC and ACHC If:

  • Your health plan and payer contracts require ACHC
  • Different manufacturers or payers require URAC and ACHC
  • Your pharmacy is large enough to absorb the operational and consulting overhead of dual accreditation
  • Competitive differentiation in both general specialty and rare disease markets is a strategic priority

Common Comparison Questions

Does holding URAC Specialty Pharmacy Accreditation automatically qualify a pharmacy for Rare Disease Certification?

No. Holding Specialty Pharmacy Accreditation satisfies the prerequisite accreditation requirement, but the five Rare Disease standards must be separately prepared, documented, and surveyed. Many pharmacies hold Specialty Pharmacy Accreditation for years before pursuing Rare Disease Certification — and discover that their existing patient management infrastructure does not satisfy the rare disease-specific standards without targeted remediation. The accreditation gets you to the starting line for Rare Disease Certification; it does not carry you across it.

How does URAC Rare Disease Certification compare to Joint Commission pharmacy accreditation?

The Joint Commission accredits pharmacies, including specialty pharmacies, through its Home Care program. Its pharmacy accreditation page does not describe a rare disease credential. IHS compares the programs against your manufacturer and payer contracts in the discovery session.

Is URAC Rare Disease Pharmacy Certification recognized by all rare disease manufacturers?

No individual accrediting body's credential is universally recognized or required by every manufacturer in every therapeutic category. Manufacturer network access decisions are made by each manufacturer independently, and criteria vary. URAC Rare Disease Pharmacy Center of Excellence Certification is a rare disease-specific quality credential in the specialty pharmacy space and can be a factor in manufacturer network selection. It does not guarantee access to any specific network.

Does ACHC have a rare disease pharmacy credential?

Yes. ACHC offers a distinction in Rare Diseases and Orphan Drugs, which ACHC says must be earned with, or after, its own pharmacy accreditation. URAC offers the Rare Disease Pharmacy Center of Excellence Certification. Each sits on that accreditor's base accreditation, so the choice turns on which accreditor your manufacturer partners and payers ask for.

My pharmacy already holds ACHC accreditation. Can we also pursue URAC Rare Disease Certification?

Yes, but you would add URAC Specialty Pharmacy Accreditation; ACHC accreditation does not satisfy the prerequisite. A pharmacy holding ACHC accreditation but not URAC Specialty Pharmacy Accreditation can add URAC Specialty Pharmacy Accreditation and layer Rare Disease Certification on it. This means a dual accreditation path (ACHC + URAC Specialty Pharmacy + URAC Rare Disease Certification). If your manufacturers accept ACHC's distinction, you may not need the URAC path. IHS evaluates whether that path makes strategic and operational sense for your specific organization before recommending it.

IHS Perspective: What the Certification Signals

The certification is designed to identify pharmacies with the clinical infrastructure, multidisciplinary team structure, disease-specific programming, and outcomes analytics to serve patients who have few treatment options and no margin for pharmacy failures.

For pharmacies that meet the eligibility criteria and have the operational foundation to pursue it, URAC Rare Disease Certification is one way to show rare disease capability to manufacturers and payers. Thomas G. Goddard, JD, PhD, former Chief Operating Officer and General Counsel of URAC, leads IHS URAC engagements.

Schedule a Free Discovery Session

IHS offers a complimentary discovery session to help your pharmacy determine which accreditation path — URAC Specialty Pharmacy Accreditation, URAC Rare Disease Pharmacy Center of Excellence Certification, ACHC, or a combination — is appropriate given your drug portfolio, existing accreditation posture, and market objectives. Bring your drug list, your current accreditation status, and your contracting priorities.

Schedule a Free Discovery Session

Talk with IHS's CEO

A 30-minute introductory meeting with Thomas G. Goddard, JD, PhD, to scope what your organization needs.

Schedule a Free Discovery Session